UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Emerging Growth Company ☐ FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2024 OR ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: 001-37985 ANAPTYSBIO, INC. (Exact name of registrant as specified in its charter) Delaware 20-3828755 (State o ...

Financial Performance - Cash and investments totaled $458.0 million as of September 30, 2024, an increase of $40.1 million from $417.9 million as of December 31, 2023[8]. - Collaboration revenue was $30.0 million for the three months ended September 30, 2024, compared to $3.3 million for the same period in 2023, representing a significant increase[9]. - Net loss was $32.9 million for the three months ended September 30, 2024, compared to a net loss of $37.3 million for the same period in 2023[12]. - Total operating expenses for Q3 2024 were $52,774,000, up from $41,050,000 in Q3 2023, reflecting an increase of 28%[18]. - Net loss for Q3 2024 was $32,851,000, an improvement from a net loss of $37,308,000 in Q3 2023, indicating a reduction of 12%[18]. - Comprehensive loss for Q3 2024 was $(31,677,000), compared to $(36,047,000) in Q3 2023, showing a decrease of 12%[18]. - Basic and diluted net loss per common share for Q3 2024 was $(1.14), compared to $(1.41) in Q3 2023[18]. Research and Development - Research and development expenses were $42.2 million for the three months ended September 30, 2024, up from $30.9 million in the same period in 2023[10]. - Research and development expenses rose to $42,212,000 in Q3 2024, compared to $30,878,000 in Q3 2023, marking an increase of 37%[18]. - ANB032 Phase 2b trial in atopic dermatitis is expected to report top-line data in December 2024, with approximately 200 patients enrolled[3]. - Rosnilimab Phase 2b trial in rheumatoid arthritis is expected to report top-line data in February 2025, with approximately 420 patients enrolled[4]. - Phase 1 trial for ANB033, an anti-CD122 antagonist, was initiated in October 2024, with Phase 1b indication expected to be disclosed in 2025[6]. Expenses - General and administrative expenses were $10.6 million for the three months ended September 30, 2024, compared to $10.2 million for the same period in 2023[11]. - Total other (expense) income, net for Q3 2024 was $(10,094,000), a decline from $424,000 in Q3 2023[18]. - Non-cash interest expense for the sale of future royalties increased to $(15,413,000) in Q3 2024 from $(4,431,000) in Q3 2023[18]. Cash and Funding - The company reiterates its cash runway through year-end 2026, supported by recent funding activities[8]. - Interest income for Q3 2024 increased to $5,324,000 from $4,854,000 in Q3 2023, representing a growth of 10%[18]. - The weighted-average number of shares outstanding for Q3 2024 was 28,893,000, up from 26,546,000 in Q3 2023[18]. Licensing and Collaboration - The company intends to out-license imsidolimab, a cytokine antagonist, in 2024[6]. - Collaboration revenue for Q3 2024 was $30,017,000, a significant increase from $3,318,000 in Q3 2023, representing a growth of 804%[18].

SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its senior management team, are scheduled to participate in multiple upcoming investor conferences: Guggenheim's Inaugural Healthcare Innovation Conference, Boston, MA Format – Fireside chat and one-on-one investor meetingsDate a ...

Core Insights - AnaptysBio, Inc. is focused on developing innovative immunology therapeutics, with key upcoming clinical data releases for its drug candidates ANB032 and rosnilimab in atopic dermatitis and rheumatoid arthritis, respectively [1][2][3][4] Clinical Development Updates - Top-line Phase 2b data for ANB032, a BTLA agonist, is expected in December 2024, with approximately 200 patients enrolled in a placebo-controlled trial [3] - Top-line Phase 2b data for rosnilimab, a PD-1 agonist, is anticipated in February 2025, following the completion of enrollment of around 420 patients [4] - A Phase 1 trial for ANB033, an anti-CD122 antagonist, has been initiated in healthy volunteers, with further indications expected in 2025 [5] Financial Performance - As of September 30, 2024, the company reported cash and investments totaling $458.0 million, an increase from $417.9 million at the end of 2023, primarily due to a $100.0 million offering and $50.0 million from royalty monetization [7] - Collaboration revenue for Q3 2024 was $30.0 million, significantly up from $3.3 million in Q3 2023, driven by a commercial milestone from Jemperli sales [7] - Research and development expenses rose to $42.2 million for Q3 2024, compared to $30.9 million in Q3 2023, reflecting increased development costs for key drug candidates [7] Pipeline Overview - The company has multiple programs in clinical development, including ANB032 for atopic dermatitis, rosnilimab for rheumatoid arthritis and ulcerative colitis, and ANB101, a BDCA2 modulator, which is set to enter Phase 1 trials in Q1 2025 [9] - AnaptysBio also has legacy cytokine antagonist programs available for out-licensing, including imsidolimab, which has completed Phase 3 trials for generalized pustular psoriasis [5][9]

SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its senior management team, are scheduled to participate in multiple upcoming investor conferences: 2024 Wells Fargo Healthcare Conference, Boston, MA Format – Fireside chat and one-on-one investor meetingsDate and Time – Thursda ...

The company's immediate future looks promising, as it has a drug that should get a clinical readout within months and a deep-pocketed pharmaceutical peer as an investor.Clinical-stage biotech AnaptysBio (ANAB -1.30%) has recently been something of a standout, at least on the stock exchange. According to data compiled by S&P Global Market Intelligence, the clinical-stage biotech's share price had increased by nearly 10% week to date as of Friday before market open. Although there was little market-moving dir ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2024 OR ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: 001-37985 ANAPTYSBIO, INC. (Exact name of registrant as specified in its charter) Delaware 20-3828755 (State or other jurisdiction of incorpo ...

Anaptys Announces Second Quarter 2024 Financial Results and Provides Business Update • Top-line data expected in December 2024 after having completed enrollment for Phase 2b trial to treat atopic dermatitis (AD) with ANB032, our BTLA agonist • Top-line data accelerated and now anticipated in Q1 2025 for Phase 2b trial to treat rheumatoid arthritis (RA) with rosnilimab, our PD-1 agonist • Top-line data now anticipated in Q1 2026 for Phase 2 trial to treat ulcerative colitis (UC) with rosnilimab • IND accepte ...

Wall Street expects a year-over-year increase in earnings on higher revenues when AnaptysBio, Inc. (ANAB) reports results for the quarter ended June 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they miss, the stock ma ...

Loading...Loading...HC Wainwright analyst initiated coverage on AnaptysBio Inc ANAB, a clinical-stage biotechnology company focused on delivering immunology therapeutics.AnaptysBio has a pipeline of checkpoint agonists, including rosnilimab, a PD-1 agonist in development for rheumatoid arthritis (RA) and ulcerative colitis (UC), and ANB032, a B and T cell lymphocyte attenuator (BTLA) agonist in development for atopic dermatitis (AD).In Phase 1, rosnilimab showed a 90% reduction of T cell proliferation, infl ...